Weight loss drugs could help with binge eating disorder
· Medical Xpressedited by Swati Mestri, reviewed by Andrew Zinin
Swati Mestri
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Drugs commonly used for weight loss, known as GLP-1 receptor agonists, have been found to reduce the key symptoms of binge eating disorder in a new review of evidence led by University College London (UCL) researchers.
The systematic review and meta-analysis, published in eClinicalMedicine, found that weight loss drugs can reduce binge eating episodes, loss-of-control eating and emotional eating, highlighting their potential role in treating binge eating disorder as well as obesity.
Lead author Dr. Ilaria Costantini (UCL Psychiatry) said, "Binge eating disorder, where people regularly eat an excessive amount of food while feeling they have lost control, is common and highly impairing, affecting over 17 million people worldwide.
"But treatment options are limited and there are currently no approved medications, so there remains a need for better ways to help people living with this condition. We found evidence that weight loss drugs may help to manage some key symptoms of binge eating disorder."
In the largest study to date on the subject, the researchers pulled together evidence from 25 randomized controlled trials that took place in 12 countries on four continents, including data from 8,069 participants.
The studies tested the effects of drugs targeting the appetite-regulating hormone GLP-1, such as semaglutide (often marketed under brand names Ozempic or Wegovy), tirzepatide (also known as Mounjaro) and liraglutide.
These drugs can suppress appetite by targeting the central nervous system and insulin secretion, and they can delay stomach emptying while also potentially influencing brain processes of reward and impulse control.
The researchers found that the drugs yielded benefits beyond weight loss, including reducing binge eating, loss-of-control eating and emotional eating.
Participants also reported increased cognitive or dietary restraint (which relates to how much people intentionally limit their eating), but the researchers say more research is needed to understand this link.
The study's first author, Ph.D. candidate Izzy Emptage (UCL Psychiatry), said, "From the evidence available, we cannot say whether the increase in dietary restraint reflects a positive and helpful form of self-regulation or if it is a more dysfunctional pattern of eating. We hope that future research can clarify whether or not taking weight loss drugs might contribute to more pathological forms of eating restriction such as meal skipping."
The researchers say their findings demonstrate that weight loss drugs could be an important part of treatment plans for people with binge eating disorder, alongside psychological therapies and social support.
Emptage added, "Many people with binge eating disorder cannot access weight loss drugs through their public health care providers, so many have to seek treatment privately at considerable personal cost.
"We hope that by highlighting the potential of weight loss drugs to help with binge eating symptoms, our findings will lead to further funding of larger high-quality studies in this area to better understand how these medications could be used in practice and improve treatment options."
Costantini said, "One strength of our study is the involvement of a lived experience panel, which shared important insights into views and concerns about the use of these medications for binge eating, as well as the challenges many people face in accessing treatment for binge eating disorder. Importantly, panel members emphasized that sustainable recovery is likely to depend not only on medication but also on psychological therapies and social support, as well as policy- or community-level approaches to tackle societal norms and weight bias."
The researchers note the limitations of their study, as most of the trials included in the review had a high risk of bias and were funded by pharmaceutical companies. They also rarely included participants with a clinical diagnosis of binge eating disorder, which the researchers say limits the certainty of the findings.
They say that robust, independently funded randomized controlled trials with long follow-up periods that include people diagnosed with binge eating disorder are still needed to clarify the potential clinical role of these drugs in treating binge eating disorder and determine whether the observed short-term benefits translate into meaningful and sustained improvements.
Publication details
The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis, EClinicalMedicine (2026). DOI: 10.1016/j.eclinm.2026.104007
Journal information: EClinicalMedicine
Key medical concepts
Binge-Eating DisorderGlucagon-Like Peptide-1 Receptor AgonistsSemaglutide
Clinical categories
PsychiatryPsychology & Mental healthClinical pharmacologyWeight management Provided by University College London Who's behind this story?
Swati Mestri
Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Weight loss drugs could help with binge eating disorder (2026, July 15) retrieved 16 July 2026 from https://medicalxpress.com/news/2026-07-weight-loss-drugs-binge-disorder.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.